Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Insulin Icodec Injection Sites in Type 2 Diabetes
NCT04582448Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin icodec in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin icodec concentration-time curve after a single dose at Day 1. Started Oct 2020; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04582448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04582448.